Patients on tolvaptan had an eGFR decline of 1.40 mL/min/1.73 m² per year. Annual rate of eGFR decline in patients on tolvaptan was slower than in historical controls. Routine use of tolvaptan in ...

Patients were randomized to tolvaptan 30 mg/day compared with placebo in addition to standard medical therapy for a minimum of 60 days. Jennifer E. Ho, MD, Cardiology Fellow, University of ...

Oral administration of the vasopressin V2-receptor antagonist tolvaptan is safe and effective for the treatment of chronic hyponatremia in the long term, according to the results of the SALTWATER ...